T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab [Breast Cancer]

Conclusion
Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumab.

Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Dzimitrowicz, Berger, Vargo, Hood, Abdelghany, Raghavendra, Tripathy, Valero, Hatzis, Pusztai, Murthy Tags: Chemotherapy Breast Cancer Source Type: research